Secretome Therapeutics, a biotechnology company developing therapies derived from neonatal cardiac progenitor cells (nCPCs) for cardiovascular diseases, raised $20.4 million in funding.
Investors were not disclosed in the official press release.
Secretome Therapeutics is focused on creating innovative treatments for serious heart and inflammatory conditions. Their work revolves around using special cells called neonatal cardiac progenitor cells (nCPCs).
With fresh funds, Secretome plans to initiate clinical trials for its lead product focusing on cardiac disease.
In the official press announcement, Vinny Jindal, Co-Founder, President, and CEO of Secretome Therapeutics, stated: “We are grateful to have investors who share our vision and whose support enables Secretome to become a world-class drug development company.”
“Stem cells have shown extraordinary therapeutic potential, but challenges that include manufacturing inconsistencies have limited their broader application. Our neonatal CPC platform delivers unmatched consistency and potency, positioning Secretome to become a clear leader in this emerging area of medicine,” added Vinny Jindal.